Evidence map›Paper›PMID 32737747›Full record

ArticleMycopathologia2020

Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China.

Ge Song, Guanzhao Liang, Weida Liu

Open access · greenAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Mycopathologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 295 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
295citing papers in PubMed, 8 pooled it
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

295 citing papers in PubMed, 8 syntheses or guidelines pooled it, 644 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Review
  10. Review
  11. Pulmonary Artery Mass Caused byInfectious disease reports · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

235 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ge SongDepartment of Medical Mycology, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College & Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, 210042, China.
Guanzhao LiangDepartment of Medical Mycology, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College & Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, 210042, China.
Weida LiuDepartment of Medical Mycology, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College & Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, 210042, China. liumyco@hotmail.com.
Chinese Academy of Medical Sciences Dermatology Hospital · CN

Funding

The subitem of the Important and Special Project of the Science and Technology Ministry of China and National Pathogen Resource Center 2018ZX10734404
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been sweeping across the globe. Based on a retrospective analysis of SARS and influenza data from China and worldwide, we surmise that the fungal co-infections associated with global COVID-19 might be missed or misdiagnosed. Although there are few publications, COVID-19 patients, especially severely ill or immunocompromised, have a higher probability of suffering from invasive mycoses. Aspergillus and Candida infections in COVID-19 patients will require early detection by a comprehensive diagnostic intervention (histopathology, direct microscopic examination, culture, (1,3)-β-D-glucan, galactomannan, and PCR-based assays) to ensure effective treatments. We suggest it is prudent to assess the risk factors, the types of invasive mycosis, the strengths and limitations of diagnostic methods, clinical settings, and the need for standard or individualized treatment in COVID-19 patients. We provide a clinical flow diagram to assist the clinicians and laboratory experts in the management of aspergillosis, candidiasis, mucormycosis, or cryptococcosis as co-morbidities in COVID-19 patients.

Indexed as

Candidiasis, InvasiveChinaCoronavirus InfectionsCOVID-19CryptococcosisHumansInvasive Pulmonary AspergillosisMucormycosisMycosesPandemicsPneumonia, ViralAspergillosisCandidiasisCOVID-19Fungal co-infectionSARS-CoV-2

Identifiers

PMID32737747
PMCPMC7394275
OpenAlexW3046718123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.